We
previously outlined
the growing threat of securities class action lawsuits against life sciences companies and the importance of the United States Supreme Court’s decision in Omn...
Boston-based biotech Intarcia Therapeutics announced this week that it had secured $225 million in aprivate synthetic royalty financing. The financing is in the form of limited recourse n...
Many companies voluntarily impose a “blackout period” beginning around the time a quarter ends and continuing through the quarter’s earnings announcement or subsequent 10-Q or 10-K ...
The SEC staff has issued frequently asked questions on the JOBS Act. Below are new FAQs most likely to be of interest to capital markets participants. We will continue to provide JOBS Act...
On April 5, 2012, the President signed into law the Jumpstart Our Business Startups Act (the “JOBS Act”), the most significant Congressional relaxation in memory of restrictions surro...
Today President Obama signed into law the Jumpstart Our Business Startups Act (the “JOBS Act”). The JOBS Act includes provisions that ease the IPO process and subsequent public report...
While the U.S. IPO market has slowed down in recent months, Davis Polk’s pipeline of deals in progress is strong, leading us to believe that there will be an uptick in IPO transactions ...
The U.S. IPO market, which has been in the doldrums since 2007, has recently been showing signs of life. We have recently completed several large transactions, and our pipeline of deals i...
After a year of proposed rulemaking, the US Securities and Exchange Commission (SEC) recently finalized the first amendments to its reserves and other reporting requirements for the oil a...
